Medical device manufacturer reshores production; invests $100 million in U.S. facility

SourcePlastics Today
Date Published09/06/2017
Author NameNorbert Sparrow
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Insulet Corp.
Type of work Manufacturing
If manufacturing, is the company a contract manufacturer?Yes
Reshoring category:Reshoring
Total number of jobs (added or to be added):200
Year reshoring announced:2017
Domestically, the work will be done:In-house
Capital investment ($):100
Country(ies) from which reshored:China
City reshored to:Acton
State(s) reshored to:MA
If relevant, work nearshored to:-
Product(s) reshoreddrug-delivery and insulin-management devices
What non-domestic negative factors made offshoring less attractive?Quality/rework/warranty, Rising wages
What domestic positive factors made reshoring more attractive?Automation/technology, Customer responsiveness improvement, Lead time/Time to market, Proximity to customers/market
Find Reshoring Articles